1-tert-Butyl-hexahydro-pyrimidin | 15974-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-tert-Butyl-hexahydro-pyrimidin
• 英文别名: 1-Tert-butyl-1,3-diazinane
• CAS: 15974-00-2
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: HYMKTHAZGZEHIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Hydroxamate-Based Inhibitors of Deacetylases
  申请人：CHO Young Shin

  公开号：US20110053925A1

  公开（公告）日：2011-03-03

  The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , ring A, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

  本教导涉及到Formula I的化合物，以及其药用盐、水合物、酯和前药，其中R1、R2、R3、环A和如此定义。本教导还提供了制备Formula I化合物的方法，以及利用Formula I化合物治疗、抑制或预防完全或部分由去乙酰酶介导的病理状况或紊乱的方法。
• MYC G-quadruplex stabilizing small molecules and their use
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10196372B2

  公开（公告）日：2019-02-05

  Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.

  本文公开了治疗肿瘤（如良性或恶性肿瘤）的方法。这些方法包括向受试者施用治疗有效量的小分子，这种小分子可选择性地与 c-MYC 基因启动子中的 G-四叠体 DNA 结合并使其稳定。这些方法还可用于减少转移灶的大小和/或数量。还提供了用于所公开方法的化合物。
• Compositions and methods for treating diseases and conditions
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10487076B2

  公开（公告）日：2019-11-26

  A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s—NH—(CH2)t, (CH2)s—O—(CH2)t, or (CH2)s—C(NH2)—(CH2)v—NH—(CH2)t, where s, t and v are each, independently an integer from 1 to 5; A and B are each, independently, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; C and D are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl, each optionally substituted with 1, 2 or 3 independently selected Rg groups; each Rg is, independently, halogen, C1-6 alkyl, C1-6 haloalkyl, hydroxyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, or di-C1-6alkylamino; and n1 and p1 are each, independently, integers from 1 to 10.

  式 II 的化合物或其盐、酯、溶液、水合物或原药： 其中 X1 是支链或未支链的 C1-10 烷基、(CH2)s-NH-( )t、( )s-O-( )t 或 ( )s-C(NH2)-( )v-NH-( )t ，其中 s、t 和 v 各自独立地为 1 至 5 的整数； A 和 B 各自独立为 C6-10 芳基、C6-10 芳基-C1-6烷基、C3-9 杂芳基或 C3-9 杂芳基-C1-6烷基，各自任选被 1、2 或 3 个独立选择的 Rg 基团取代； C 和 D 各自独立为 C3-7 环烷基、C3-7 环烷基-C1-6烷基、C3-7 杂环烷基、C3-7 杂环烷基-C1-6烷基、C6-10 芳基、C6-10 芳基-C1-6烷基、C3-9 杂芳基或 C3-9 异芳基-C1-6烷基，各自任选被 1、2 或 3 个独立选择的 Rg 基团取代； 每个 Rg 独立地是卤素、C1-6 烷基、C1-6 卤代烷基、羟基、C1-6 烷氧基、C1-6 卤代烷氧基、氨基、C1-6 烷基氨基或二-C1-6 烷基氨基；以及 n1 和 p1 各自独立地为 1 至 10 的整数。
• Azaindoles as inhibitors of HPK1
  申请人：Genentech, Inc.

  公开号：US10952995B2

  公开（公告）日：2021-03-23

  Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.

  本文描述了氮杂吲哚化合物及其作为 HPK1 抑制剂的用途。 这些化合物可用于治疗 HPK1 依赖性疾病和增强免疫反应。 还描述了抑制 HPK1 的方法、治疗 HPK1 依赖性疾病的方法、增强免疫反应的方法以及制备氮杂吲哚化合物的方法。
• Kinase Inhibitor And Use Thereof
  申请人：XUANZHU PHARMA CO., LTD.

  公开号：US20160332989A1

  公开（公告）日：2016-11-17

  The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.